Biotech | August 31, 2021
US FDA grants Lantern Pharma additional Orphan Drug tag for LP-184
The drug is also intended for the treatment of glioblastoma multiforme
The drug is also intended for the treatment of glioblastoma multiforme
The submission to the US FDA has been initiated and they intend to file these data with the European Medicines Agency and other regulatory bodies in the coming weeks
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
It measures 9 French (3 millimetres) in diameter upon insertion and removal from the body. While in the heart, it expands to support the heart’s pumping function, providing flow greater than 3.5 L/min
Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
Deal for 100 million doses with additional 100 million through 2023
The vaccine was 85 percent effective in preventing severe disease across all regions.
Subscribe To Our Newsletter & Stay Updated
